The ongoing pandemic response by the biopharma industry has been historic. Biotech companies and contract development and manufacturing organizations, along with the entire supply chain, have worked together to develop several SARS-CoV-2 vaccines, achieved Emergency Use Authorization(EUA) from the FDA, and began delivering desperately needed protection into people’s arms in less than a calendar year.
For three years VaLogic LLC and the Frederick Community College Biotechnology Program have worked hand-in-hand to build a partnership, including a new biotech apprenticeship program, that provides a pathway for students to gain employment in the fast-growing life sciences ecosystem in Maryland.
The Germantown Innovation Center is home to some of Maryland’s fastest-rising stars in the life sciences ecosystem. Multiple startups found a home in the Montgomery County incubator and benefit from the lab space and the strategic access to federal agencies, nearby thought leadership, and on-campus workforce access.
The ongoing COVID-19 pandemic greatly exposed a dearth of essential medications and significant vulnerabilities in the United States medical supply chain. Phlow Corporation aims to mitigate those weaknesses and manufacture essential generic medications at its Virginia manufacturing facility.
The Discovery Labs’ 2.4 million square foot site in King of Prussia, PA provides all the necessary ingredients to accelerate speed to market for cell and gene therapy innovators. The Center for Breakthrough Medicines is a cell and gene therapy contract development and manufacturing organization (CDMO) for plasmid DNA, viral vectors, and cellular therapy products and is located on-site.
Identifying gaps and bridging them—that’s what Connected DMV’s President and CEO Stu Solomon does best. And now he and his partners are turning their attention to one of the globe’s most important and challenging divides: Preparing for the next pandemic.
The National Institutes of Health provides significant funding for drug development research to universities, companies, and organizations. Over the course of 2020, the NIH provided a significant amount of funding to the BioHealth Capital Region.
As one of the world’s top bio hubs, the BioHealth Capital Region (BHCR) is rife with life science assets. The region has been at the forefront of the SARS-CoV-2 vaccine race and it is rapidly becoming a center for advanced manufacturing. The BHCR cell and gene therapy ecosystem is thriving, and the area boasts one of the richest and most diverse tapestries of life science talent and workforce development programming. What’s more, Maryland, Washington, DC, and Virginia are home to several dynamic university systems that keep the talent and tech transfer pipeline humming and full.
Seraxis, which is currently located at the Pinkney Innovation Complex for Science & Technology at Montgomery College (PIC MC) in the County-owned Germantown Innovation Center is developing its lead therapy, SR-01, to eliminate the need for type 1 diabetes patients to inject insulin. SR-01 is a revolutionary therapy that could impact more than 4.5 million people in the world.
85,000 square foot state-of-the-art facility being built in Rockville, MarylandAccelerates TCR2s commercial-scale manufacturing timelines with production anticipated in 2023Aaron Vernon hired…
